in 2006, the FertiPROTEKT network was founded. It has meanwhile been extended to cover all German-speaking countries (Germany, Switzerland, Austria).
Wer sind wir?
It gives women and men facing or having gone through chemo- or radiotherapy the chance to obtain the most recent scientific advice about their fertility and the measures which can be taken to protect it.
By contrast to men, where the preservation of sperm is an established method, effective techniques of fertility protection for women have only been around for a few years.
FertiPROTEKT is internationally one of the the first networks offering these techniques to a whole nation. Within the network, these methods are being established, further developed and tested in terms of their effectiveness. Accordingly, all centres of the network meet strict constantly controlled and optimised standards of consultancy and therapy.
Currently, the network covers mostly university centres working locally and in close cooperation with oncologists of all disciplines. Further university centres, hospitals and private fertility clinics meeting the strict quality standards are joining the network.
The FertiPROTEKT homepage informs you about the background and therapies, costs and effectiveness (“Illnesses” and “Treatment methods”). You can also find out about the structure of the network (“FertiPROTEKT — The Network”) as well as about the statistical data of the patients treated by FertiPROTEKT (“FertiPROTEKT — The Register”) and recommended contact addresses of FertiPROTEKT centres (“Cooperating centers and contacts”). If any information on the homepage seems unclear to you or you have problems with the contact, the advice or the therapy provided by one of the centres, please do not hesitate to inform the coordinators. A translation into English is coming soon.
We hope to be offering plenty of information on our homepage and wish you and your patients good health and all the best,
Your FertiPROTEKT team
Other malignant diseases
Here you will find information about fertility preservation relating to other malignancies and cancers.
Here you will find information about fertility preservation in children who are affected by a malignant disease.
Turner syndrome is a genetic disorder (inherited disease) where there is the loss of an X chromosome or a limitation of its function.
Endometrial carcinoma affects women under the age of 40 in 3–14% of cases.
Ovarian tumours can be varied in nature. So-called borderline tumours make up 31%, epithelial tumours 50% and malignant germ cell tumours 19% during reproductive age. These tumours have different prognoses.
Cervical cancer is still the second most common cancer in women worldwide. Currently, one in two women is under 35 years of age at the time of initial diagnosis.
Autoimmune diseases often affect young women of childbearing age. Despite large advances in treatment, general rheumatic diseases such as connective tissue diseases and vasculitis are still often the reason for chemotherapy.
This cancer of the lymphatic system is often diagnosed in women of reproductive age. With appropriate chemotherapy, it has a very high cure rate.
CRYOCONSERVATION OF SPERM AND TESTICULAR TISSUE
Male germ cells (sperm) can be cryopreserved (frozen) before chemotherapy or radiotherapy and, in the case of a loss of function of a male patient’s gonads (testes), are used to conceive his own child.
RELOCATION OF THE OVARIES
The aim of moving the ovaries (transposition of the ovaries) is to retain their function despite planned radiotherapy. The goals are the preservation of hormone production and also the possibility of pregnancy after oncological treatment